Kalos Therapeutics

Biotechnology, Health Care, Therapeutics
Founded in 2005-01-01
San Diego, California, United States
http://kalostherapeutics.com
For Profit

About Kalos Therapeutics

Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer. Kalos is aggressively targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation). Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small-molecule compounds.

Company Metrics

  • Employees: 1-10
  • Monthly Visits: None
  • Tech Stack: 2 active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 958028 USD
  • Last Funding: 958028 USD (Convertible Note)
  • Funding Status:

Technology Stack

Kalos Therapeutics actively uses 2 products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Therapeutics

Headquarters: San Diego, California, United States